Investigations of humans with disorders of sex development (DSDs) resulted in the discovery of many of the now-known mammalian sex-determining genes, including SRY, RSPO1, SOX9, NR5A1, WT1, NR0B1, and WNT4. Here, the locus for an autosomal sex-determining gene was mapped via linkage analysis in two families with 46,XY DSD to the long arm of chromosome 5 with a combined, multipoint parametric LOD score of 6.21. A splice-acceptor mutation (c.634-8T>A) in MAP3K1 segregated with the phenotype in the first family and disrupted RNA splicing. Mutations were demonstrated in the second family (p.Gly616Arg) and in two of 11 sporadic cases (p.Leu189Pro, p.Leu189Arg)-18% prevalence in this cohort of sporadic cases. In cultured primary lymphoblastoid cells from family 1 and the two sporadic cases, these mutations altered the phosphorylation of the downstream targets, p38 and ERK1/2, and enhanced binding of RHOA to the MAP3K1 complex. Map3k1 within the syntenic region was expressed in the embryonic mouse gonad prior to, and after, sex determination. Thus, mutations in MAP3K1 that result in 46,XY DSD with partial or complete gonadal dysgenesis implicate this pathway in normal human sex determination.
of the affected individual, manifested by the degree of masculinization or feminization of the gonads and internal and/or external genitalia, is often determined by the specific genetic mutations and, presumably, modifier genes. Individuals may be completely masculinized or feminized or have ambiguous genitalia.
The heritable nature of 46,XY DSD was identified in the 1970s. [13] [14] [15] These studies anticipated sex-limited transmission of an autosomal-dominant or X-linked trait from parents with the nonpenetrant genotype (46,XX) to those with the penetrant genotype (46,XY), accounting for the obvious lack of reproductive fitness. Most of these families were lost to follow-up, but one was recruited in the 1990s for future linkage and positional cloning studies and is reported here. 15 Another family, with 11 affected individuals, was reported in 2003. 16 Here, we describe mutations in MAP3K1 (MIM 600982) (also known as MEKK1) that are associated with both familial and sporadic cases of 46,XY DSD, including one in the index family. These studies add MAP3K1 and the mitogen-activated protein kinase (MAPK) signaling pathway to the repertoire of genetic pathways that control normal human testis development and identify mutations in this gene as a prevalent cause of 46,XY DSD. In 2003, we mapped a gene, which, when mutated, was likely to be causative of the phenotype in family 1, to the long arm of chromosome 5. 17 This family was from France, was of European descent, and included six women with 46,XY complete (IV-3 and IV-21 in Figure 1 and Table S1 [available online]) or partial (II-12, III-35, IV-2, and IV-27) gonadal dysgenesis. One of the women with partial gonadal dysgenesis (II-12) had clitoral hypertrophy and hirsutism. Three of the women had gonadal tumors (III-35, IV-2, and IV-3). Four men had genital abnormalities, including one with first-degree hypospadias with chordee (III-29) and three with perineal hypospadias (II-10, III-13, and IV-28). One of these individuals had micropenis and cryptorchidism (III-13). The man with first-degree hypospadias and chordee had normal fertility and fathered two children: one with perineal hypospadias and chordee (IV-28) and the other with 46,XY partial gonadal dysgenesis . No extraurogenital abnormalities were observed in any individuals. Family 2 was from New Zealand and included five females with complete gonadal dysgenesis (II-5, II-6, II-7, III-4, and IV-2). This family was of Northern European origin and had a maximal LOD score of 1.14 at D5S2068 (see Table S2 for LOD scores and Table S3 for primer sequences). The combined LOD score for both families was 4.62 at D5S398; the multipoint LOD score was 6.21. On the basis of linkage recombination breakpoints, the critical region between D5S1969 and D5S2028 encompassed 5 Mb of DNA and 34 candidate genes. Only two genes within this region, Map3k1 ( Figure 2 ) and Mier3 (data not shown), demonstrated high levels of expression within 13.5 days postcoitum (dpc) in mouse gonads, and the expression was approximately equal in male and female gonads, as previously reported.
18 Map3k1 expression was also observed throughout the mouse embryonic gonad at 11.5 dpc, the sex-determining stage of gonad development ( Figure 2B ). 19 Staining occurred within the testis cords at 13.5 dpc in a pattern indicative of Sertoli cell expression ( Figure 2H ).
Sequence analysis of MIER3 (NM_152622.3) and MAP3K1 (NM_005921.1) (Table S4 ) in affected individuals in the French family 1 identified only one previously unidentified heterozygous variant in the polypyrimidine track of the splice-acceptor site in intron 2 of MAP3K1 (c.634-8T>A) that segregated with the phenotypes ( Figure 3A ). This variant of MAP3K1 was not observed in 100 unrelated French individuals of European descent or in the 1000 Genomes Project. Given the proximity of this variant to the intron-exon boundary, a quantitative PCR assay was developed to test the efficiency or fidelity of mRNA splicing at this exon (Table S5 ). The level of expression for the normal and affected samples was not significantly different ( Figure S1 ). However, variant cDNAs resulting in heteroduplex molecules were identified in samples from affected individuals by a second peak in the SYBR-green-based qPCR dissociation curves ( Figure 3B ). The splice products were analyzed by cloning and sequencing. The cloned cDNAs from the affected samples demonstrated both wild-type and aberrant splicing that resulted in the addition of six nucleotides into the RNA (c.633_634insAATCAG) and two amino acid residues (p.Val211_Val212insIleGln) into the protein in-frame at this site ( Figure 3C ). The ratio of the mutant to wild-type transcript was > 1 in the lymphophoblastoid cells of individuals carrying the mutation ( Figure S1 [p.Leu189Pro] and c.566T>G [p.Leu189Arg]) ( Figure 3A ). None of these variants was reported previously as a known SNP, nor were they observed in 100 unrelated, ethnically matched individuals tested specifically in our investigation or in the 1000 Genomes Project. No mutation was observed in nine other sporadic cases of 46,XY complete gonadal dysgenesis, suggesting a mutation prevalence of 18% in this cohort. The p.Leu189Pro and p.Leu189Arg mutations were reported by PolyPhen and SIFT 20 to be likely to interfere with function, whereas the heritable p.Gly616Arg mutation was not. Nonetheless, this mutation resulted in the substitution of a basic for a conserved neutral amino acid at this site. The p.Leu189Arg mutation was observed in the patient's mother, whereas the p.Leu189Pro mutation was not. The father of the patient with the p.Leu189Pro mutation was not available for analysis. We then determined whether the mutations identified resulted in altered MAP3K1 function. Previously, it has been shown that MAP3K1 affects the MAP kinase cascade by regulating phosphorylation of the downstream targets p38 (MIM 600289), ERK1/2 (MIM 601795/MIM 176948), and JNK (MIM 605431). 21 The effects of three of the four MAP3K1 mutations on phosphorylation of downstream targets were examined by quantitative immunoblot analysis after serum starvation for 24 hr and subsequent serum refeeding for an additional 1 hr in lymphoblastoid cells.
(A cell line was not available for the p.Gly616Arg mutation.) Under these culture conditions, the phosphorylation of p38 in two out of three mutant cell lines was greater than wildtype, whereas levels of phospho-p38 in p.Leu189Pro were not altered (Figures 4A and 4B, Table S6 -these increases were observed whether normalization was performed to histone or to total p38). Levels of phospho-ERK were increased in all the mutant cell lines in comparison to wild-type (Figures 4A and 4B, Table S6 ). Thus, we conclude that regulation of the MAPK signaling pathway is disrupted by the MAP3K1 mutations reported here, causing increased activation in cultured lymphoblastoid cell lines. To identify how these MAP3K1 mutations might cause 46,XY DSD, we began by identifying their positions relative to the known protein-binding domains of MAP3K1. The intron splice-acceptor mutation in family 1 inserts two amino acids in the middle of a domain complementary to the interactive site of growth factor receptor-bound protein 2 (GRB2 [MIM 108355]), 22 and the point mutations at codon 189 occurred within the phylogenetically conserved 27 amino acid region that comprises the focal adhesion kinase (FAK) binding site (MIM 600758). 23 Most significantly, all of these mutations and the codon 616 mutation occurred in the amino third of MAP3K1, a region that has been shown to interact with RHOA (MIM 165390). 24 That study showed that RHOA positively regulates MAP3K1 kinase activity by binding to its N-terminal third, in the region in which the mutations reported here have been identified. 24 To test whether MAP3K1 mutations affected the binding of endogenous RHOA, we performed coimmunoprecipitation by immunoprecipitating mutant (c.634-8T>A) and wild-type complexes with anti-MAP3K1 and probing the immunoblot with anti-RHOA ( Figure 4C ). This experiment demonstrated that this mutation resulted in enhanced binding of RHOA in the mutant cell lines compared to wild-type. This increased binding could not be accounted for on the basis of unequal loading of MAP3K1-bearing complexes or on the basis of enhanced expression of RHOA in the mutant cell lines-as judged by immunoblot analysis ( Figure 2S ). In support of this finding, the converse immunoprecipitation experiments, with anti-RHOA, resulted in 2. no. 10417), and proper informed consent was obtained. All mice were bred under standard conditions of care and used under licensed approval from the UK Home Office (PPL 30/2381).
An earlier study used linkage analysis and positional cloning in a family with 46,XX DSD and palmoplantar keratosis to identify RSPO1 as the mutated, disease-associated gene. 5 The current study employed a similar approach to identify mutations in MAP3K1 in families with 46,XY DSD and subsequently in sporadic cases with this phenotype. These in-frame mutations provide a basis for the autosomal-dominant, sex-limited inheritance. The phenotypic variation among affected members of family 1 might be explained by the individual differences in aberrant splicing in the developing gonad and, potentially, modifier loci. In mice with a spontaneously occurring loss-of-function, 8 exon deletion of Map3k1 on a BALB/cGa background, the only reported phenotype was open eyelids at birth. 25 No genital abnormalities, skewing of the sex ratio, or infertility were reported in that study. However, unlike C57BL/6J, BALB/cGa is not a background known for its sensitivity to disruptions in testis development. One other gene in the MAP kinase pathway has an established role in sex determination. Recently, some of us (A.G., N.W., and H.O.) identified the recessive boygirl (byg) mutation, which, when homozygous on the C57BL/6J background, resulted in embryos with XY gonadal sex reversal. 26 The byg mutation, an A-to-T transversion in Map3k4 leading to a premature stop codon, caused a growth deficit in 11 dpc XY byg/byg gonads and a failure to support mesonephric cell migration, both early cellular processes normally associated with testis development. On some genetic backgrounds, XY mice merely heterozygous for a loss-of-function allele of Map3k4 developed as viable females. Homozygous mutant 11.5 dpc XY gonads demonstrated a dramatic reduction in Sox9 and Sry at the transcript and protein levels, accounting for the defect in Sertoli cell differentiation.
Here, we describe an unexpected activation of MAPK targets in human lymphoblastoid cells from the sexreversing MAP3K1 mutations. Given that loss of MAP3K4, and therefore a presumed deficit in MAPK signaling, causes XY sex reversal in mice, an apparent tension arises between observations in the two species. How might this be resolved? Members of the MAP kinase gene family could mediate the balance between the male and female sex-determining pathways by affecting the activities of the testis-promoting SOX9 and FGF9 (MIM 600921) and ovarian-promoting WNT4 and CTNNB1 (b-catenin) (MIM 116806) (reviewed in 27 ). It is worth noting that such explanations do not require sexually dimorphic expression of MAPK signaling components during gonadogenesis because transcription of SOX9, FGF9, and WNT4 is already sexually dimorphic. Previously, it has been shown that the transcriptional activity of SOX9 in chondrocytes is regulated by the MAP3K1 binding partner, RHOA, [28] [29] [30] and that the increase in SOX9 levels in chondrocytes induced by FGF2 (MIM 134920) is mediated via the MAP kinase pathway. 31 Axin (MIM 603816), a member of the MAPK complex and an inhibitor of the WNT signaling pathway, interacts with b-catenin to reduce its quantity. 32, 33 Stabilization of b-catenin in the XY gonad causes male-to-female sex reversal, in part by reducing SOX9 expression. 34 Thus, the 46,XY DSD that is associated with mutations in MAP3K1 may be caused by decreased SOX9 activity, increased b-catenin activity, or both. Sorting through these possibilities and others will require further investigation, as will determining whether the functional consequences of specific MAP3K1 mutations in lymphoblastoid cell lines are similar to those in the embryonic gonad. Indeed, disruption to (loss of) one part of the MAPK signaling network is consistent with consequential activation of other components elsewhere. In summary, we have identified mutations in MAP3K1 that cause downstream alterations in the MAP kinase signaling pathway in two familial and two sporadic cases of 46,XY DSD. Mutations in this gene, as well as in SRY, NR5A1, and DHH (MIM 605423), should be routinely tested in individuals with 46,XY DSD. 2 
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